secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2025-10-28T23:59:59+00:00
Accession:  0001171843-25-006720
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beta Bionics Q3 sales up 63% YoY to $27.3M; raises full-year 2025 guidance
--------------------------------------------------------------------------

- Net sales $27.3M (+63% YoY); DME $21.0M (+45%), PBP $6.2M (+178%).
- Gross margin 55.5% (+212 bps); net loss $14.2M vs $9.7M prior year.
- Installed base 29,419 users (+162%); new patient starts 5,334 (+68%); 70% from MDI.
- Adjusted EBITDA -$12.2M (negative 45% of sales); cash $274.0M.
- Raised full-year 2025 guidance; specific numbers not disclosed in filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000117184325006720/0001171843-25-006720-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000117184325006720/f8k_102825.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006720

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer